In vivo Pharmacokinetics Investigation of Curcumin Nanosuspensions in Rats

Abstract:

Objective: To investigate in vivo pharmacokinetics and oral bioavailability of curcumin nanosuspensions in rats. Method: The same dose of curcumin bulk drugs and curcumin nanosuspensions were orally administered to two groups of rats,After gavage 20,40 min,1,2,4,6,8,12,24 h,0.3 mL blood from retinal venous plexus was obtained to measure plasma curcumin concertration ny HPLC analysis,Xterra C₁₈ column(4.6 mm×250 mm,5 μm),C₁₈ pre-column(4.0 mm×2.0 mm),column temperature 35℃,mobile phase of methanol-1% acetic acid aqueous solution(78:22),flow rate 1.0 mL·min^-1,injection volume 20 μL.The lowest limit of quantitation of curcumin and other pharmacokinetic parameters of curcumin and curcumin nanosuspensions were determined. Result: Quantification limit of curcumin in plasma was 15 μg·L^-1(S/N>10),extraction recoveries of low,medium and high concentration were (91.3±5.7)%,(93.0±4.1)%,(93.3±5.2)%,respectively.Cmax and AUC of curcumin nanosuspensions were higher than that of curcumin bulk drugs,Cmax were (863.1±390.4),(91.8±22.9) μg·L^-1;Tmax of curcumin bulk drugs and curcumin nanosuspensions were (4.4±2.2) h and (4.8±4.4) h,t1/2 were (4.6±3.2) h and (5.4±3.7) h,there was no significant change of these two parameters. Conclusion: Established HPLC analysis was reliable and stable,curcumin nanosuspensions could significantly promote absorption of curcumin and improve its bioavailability,but no significant differences were found in both absorption and metabolic.